First, studies have reported the expression of ERβ in the range of 9–98% [9, 27, 28] in NSCLC; this inconsistency is possibly due to the heterogeneity in methodologies, including the antibodies used for immunohistochemical staining as well as inconsistent definitions of positivity. Here, ESR2 is linked to non-small cell lung carcinoma.